Tag:

Nabi Biopharmaceuticals

Latest Headlines

Latest Headlines

Biota plots U.S. move in Nabi Bio merger

Today, Nabi's new strategy took shape in the form of a merger with Australia's flu drug developer Biota, which is now moving its headquarters to the U.S.

Nabi explores options after NicVAX flunks trial

Nabi Biopharmaceuticals ($NABI) was hit hard earlier this week after the company's smoking cessation vaccine NicVAX flunked a second late-stage trial. Data showed the primary endpoint was not met in

NicVAX failure spells trouble for Nabi

Nabi Biopharmaceuticals ($NABI) quest to develop a vaccine for nicotine addiction has hit a major roadblock. In a large, Phase III study of the vaccine, just 11% of people getting NicVAX quit smoking

Nabi shares in meltdown after NicVAX flunks Ph3

Shares of Nabi Biopharmaceuticals ($NABI) went into a meltdown this morning after the developer announced that the first of two late-stage studies for its experimental nicotine addiction vaccine

Next-gen addiction vaccines offer a tough challenge to biotechs

The Wall Street Journal has taken an in-depth look at the trials and tribulations faced by a group of biotech companies determined to develop a string of vaccines to treat various addictions.

Nabi scores $540 million pact with GSK for NicVAX

Nabi Biopharmaceuticals has wrapped a licensing deal worth potentially more than $540 million with GlaxoSmithKline for its experimental therapy designed to treat nicotine addiction and prevent

Nabi lands $10M grant for NicVAX

The National Institute on Drug Abuse has given Nabi Biopharmaceuticals a $10 million loan to help fund the company's first pivotal clinical trial of NicVAX, a smoking cessation vaccine. It's the

Nabi lands $10M for anti-smoking vaccine

The National Institute on Drug Abuse has given Nabi Biopharmaceuticals a $10 million loan to help fund the company's first pivotal clinical trial of NicVAX, a smoking cessation vaccine. It's the

Nabi sells staph vax program to GSK for $46M

Nabi Biopharmaceuticals has struck a deal to sell off another big piece of itself. GlaxoSmithKline agreed to pay $46 million--$20 million upfront--for its PentaStaph program, a vaccine in development

Nabi, FDA agree on SPA for NicVAx

Nabi Biopharmaceuticals and the FDA have reached an agreement on a Special Protocol Assessment (SPA) for a Phase II trial of NicVAX, the company's anti-smoking vaccine. An SPA is a process by which